New data from a phase II trial of patients with Crohn’s disease analyzed the effect of Traficet-EN on lowering pro-inflammatory cytokine and chemokine concentrations in the intestine. These findings complement earlier data showing improved clinical endpoints in Crohn’s disease from the phase II trial.
Traficet-EN elicited a decrease in the levels of pro-inflammatory cytokines and chemokines, therefore reducing the inflammatory response in the digestive tract. In contrast, no decreases in such parameters were seen in patients on placebo.
These results are consistent with previously reported data from the phase II clinical trial designed to assess Traficet-EN’s safety and tolerability among Crohn’s patients.
“Based on preclinical studies, we believe Traficet-EN may have applications beyond Crohn’s disease to address gastrointestinal conditions where inflammation plays a key role,” said Dr Pirow Bekker, ChemoCentryx’s vice president, Medical and Clinical Affairs.
In a mouse model of Crohn’s disease, treatment with Traficet-EN resulted in significant improvement of disease, with 70% of the treated group scoring normal or mild disease and with no evidence of severe disease. In contrast, 60% of mice in the control group developed severe disease. A second set of preclinical studies in a mouse model of ulcerative colitis showed that Traficet-EN was highly effective in alleviating symptoms.